Cargando…

Pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the German population

BACKGROUND: Pharmacological neuroenhancement (PNE) refers to the use of psychoactive substances without doctor’s prescription to enhance cognitive performance or to improve mood. Although some studies have reported that drugs for PNE are also being used to cope with stressful life situations, nothin...

Descripción completa

Detalles Bibliográficos
Autores principales: Bagusat, Christiana, Kunzler, Angela, Schlecht, Jennifer, Franke, Andreas G., Chmitorz, Andrea, Lieb, Klaus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198480/
https://www.ncbi.nlm.nih.gov/pubmed/30348181
http://dx.doi.org/10.1186/s13011-018-0174-1
_version_ 1783364972863029248
author Bagusat, Christiana
Kunzler, Angela
Schlecht, Jennifer
Franke, Andreas G.
Chmitorz, Andrea
Lieb, Klaus
author_facet Bagusat, Christiana
Kunzler, Angela
Schlecht, Jennifer
Franke, Andreas G.
Chmitorz, Andrea
Lieb, Klaus
author_sort Bagusat, Christiana
collection PubMed
description BACKGROUND: Pharmacological neuroenhancement (PNE) refers to the use of psychoactive substances without doctor’s prescription to enhance cognitive performance or to improve mood. Although some studies have reported that drugs for PNE are also being used to cope with stressful life situations, nothing is known about the relationship of PNE and resilience, i.e. the ability to recover from stress. This study aimed at investigating the relationship of PNE and resilience in the first representative population sample. METHODS: A cross-sectional survey in a representative sample of 1128 adults (age ≥ 18 yrs.) living in Germany was conducted. The use of PNE and related attitudes, perceptions and behaviours were assessed by structured interviews and self-report questionnaires. Stepwise logistic regression with backward elimination was conducted to identify potential risk factors for PNE use. RESULTS: Lifetime prevalence for the use of stimulating prescription drugs without medical indication was 4.3%, 10.2% for stimulating illicit drugs, 20.3% for mood modulating prescription drugs, and 23.4% for cannabis. Coping with stressful situations was more frequently reported as underlying motive for using stimulant or mood modulating prescription drugs than stimulating illicit drugs or cannabis. The individual perceived stress increased the risk of using stimulating prescription drugs (OR: 2.86; 95% Cl: 1.49–5.46) and the individual ability to recover from stress decreased the risk of using any substance for PNE and especially mood modulating prescription drugs (OR: .62; 95% Cl: .47–.81). CONCLUSIONS: The non-medical use of prescription drugs for PNE appears to be more prevalent in subjects who are less resilient to stress. Tailored resilience interventions that improve the ability to adapt to and recover from stressors may prevent the use of prescription medication for PNE. Further research should disentangle the association between psychological resilience and PNE as well as examine the efficacy of resilience interventions in the prevention of PNE. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13011-018-0174-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6198480
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-61984802018-10-31 Pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the German population Bagusat, Christiana Kunzler, Angela Schlecht, Jennifer Franke, Andreas G. Chmitorz, Andrea Lieb, Klaus Subst Abuse Treat Prev Policy Research BACKGROUND: Pharmacological neuroenhancement (PNE) refers to the use of psychoactive substances without doctor’s prescription to enhance cognitive performance or to improve mood. Although some studies have reported that drugs for PNE are also being used to cope with stressful life situations, nothing is known about the relationship of PNE and resilience, i.e. the ability to recover from stress. This study aimed at investigating the relationship of PNE and resilience in the first representative population sample. METHODS: A cross-sectional survey in a representative sample of 1128 adults (age ≥ 18 yrs.) living in Germany was conducted. The use of PNE and related attitudes, perceptions and behaviours were assessed by structured interviews and self-report questionnaires. Stepwise logistic regression with backward elimination was conducted to identify potential risk factors for PNE use. RESULTS: Lifetime prevalence for the use of stimulating prescription drugs without medical indication was 4.3%, 10.2% for stimulating illicit drugs, 20.3% for mood modulating prescription drugs, and 23.4% for cannabis. Coping with stressful situations was more frequently reported as underlying motive for using stimulant or mood modulating prescription drugs than stimulating illicit drugs or cannabis. The individual perceived stress increased the risk of using stimulating prescription drugs (OR: 2.86; 95% Cl: 1.49–5.46) and the individual ability to recover from stress decreased the risk of using any substance for PNE and especially mood modulating prescription drugs (OR: .62; 95% Cl: .47–.81). CONCLUSIONS: The non-medical use of prescription drugs for PNE appears to be more prevalent in subjects who are less resilient to stress. Tailored resilience interventions that improve the ability to adapt to and recover from stressors may prevent the use of prescription medication for PNE. Further research should disentangle the association between psychological resilience and PNE as well as examine the efficacy of resilience interventions in the prevention of PNE. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13011-018-0174-1) contains supplementary material, which is available to authorized users. BioMed Central 2018-10-22 /pmc/articles/PMC6198480/ /pubmed/30348181 http://dx.doi.org/10.1186/s13011-018-0174-1 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Bagusat, Christiana
Kunzler, Angela
Schlecht, Jennifer
Franke, Andreas G.
Chmitorz, Andrea
Lieb, Klaus
Pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the German population
title Pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the German population
title_full Pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the German population
title_fullStr Pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the German population
title_full_unstemmed Pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the German population
title_short Pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the German population
title_sort pharmacological neuroenhancement and the ability to recover from stress – a representative cross-sectional survey among the german population
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6198480/
https://www.ncbi.nlm.nih.gov/pubmed/30348181
http://dx.doi.org/10.1186/s13011-018-0174-1
work_keys_str_mv AT bagusatchristiana pharmacologicalneuroenhancementandtheabilitytorecoverfromstressarepresentativecrosssectionalsurveyamongthegermanpopulation
AT kunzlerangela pharmacologicalneuroenhancementandtheabilitytorecoverfromstressarepresentativecrosssectionalsurveyamongthegermanpopulation
AT schlechtjennifer pharmacologicalneuroenhancementandtheabilitytorecoverfromstressarepresentativecrosssectionalsurveyamongthegermanpopulation
AT frankeandreasg pharmacologicalneuroenhancementandtheabilitytorecoverfromstressarepresentativecrosssectionalsurveyamongthegermanpopulation
AT chmitorzandrea pharmacologicalneuroenhancementandtheabilitytorecoverfromstressarepresentativecrosssectionalsurveyamongthegermanpopulation
AT liebklaus pharmacologicalneuroenhancementandtheabilitytorecoverfromstressarepresentativecrosssectionalsurveyamongthegermanpopulation